Loading
Life sciences · Journal article
Frontiers in Oncology · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality, and metastatic progression, recurrence, chemoresistance, and treatment-related toxicity continue to limit outcomes. Medical ozone has attracted interest as a potential adjunct because, after reacting with biological fluids, it generates short-lived redox mediators such as hydrogen peroxide and lipid oxidation products that may influence NRF2/Keap1, NF-κB, HIF-1α, mitochondrial apoptosis, cytokine signaling, and the tumor microenvironment. However, current CRC-specific evidence is limited and heterogeneous. Experimental studies using CRC cell lines and animal models suggest possible effects on apoptosis, oxidative stress, inflammatory modulation, hypoxia-related pathways, and chemosensitivity, but these findings remain preclinical and are not sufficient to establish antitumor efficacy. Clinical evidence in CRC patients is scarce and mainly relates to supportive care, including radiation-induced rectal injury, chronic treatment-related symptoms, and chemotherapy-induced peripheral neuropathy, rather than tumor response or survival. Importantly, ozone biology is context dependent: activation of adaptive antioxidant responses may protect normal tissues but could also enhance tumor cell stress tolerance under certain conditions. Route-specific safety is also critical, as inhaled ozone is toxic, whereas non-inhalational approaches require standardized dosing and monitoring. Overall, ozone therapy should be considered an investigational adjunct in CRC, with future studies requiring rigorous trial design, biomarker stratification, standardized administration protocols, and clear separation of anticancer endpoints from symptom-control outcomes.